SCHEMBL7521565

SCHEMBL7521565

CCNc1cc2ncnc(NCc3ccccc3N3CCCN(C)CC3)c2cc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.47
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
EGFR P00533 1/20 0.45
BRD9 Q9H8M2 6/20 0.43
BRPF1 P55201 3/20 0.43
BRD4 O60885 3/20 0.43
MET P08581 1/20 0.42
BRD7 Q9NPI1 2/20 0.41
PDE5A O76074 1/20 0.41
MAPT P10636 3/20 0.40
SIRT6 Q8N6T7 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
ALDH1A1 P00352 2/20 0.39
EIF2AK2 P19525 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NCF1 P14598 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527938 0.97 PDGFRB (0.49) PDGFRBMAPK1L3MBTL1EGFRBRD9
SCHEMBL7521455 0.93 EGFR (0.48) PDGFRBMAPK1EGFRPDE5AMAPT
SCHEMBL7530560 0.93 EGFR (0.48) PDGFRBMAPK1EGFRPDE5AMAPT
SCHEMBL7527697 0.93 EGFR (0.48) PDGFRBMAPK1EGFRPDE5AMAPT
SCHEMBL7526254 0.93 EGFR (0.48) PDGFRBMAPK1EGFRPDE5AMAPT
SCHEMBL7527163 0.89 PDGFRB (0.48) PDGFRBMAPK1L3MBTL1EGFRMET
SCHEMBL8795620 0.88 EGFR (0.45) PDGFRBMAPK1L3MBTL1EGFRMET
SCHEMBL7514367 0.88 MAPT (0.48) PDGFRBL3MBTL1EGFRBRD9BRD4
SCHEMBL7528018 0.88 EGFR (0.47) PDGFRBMAPK1EGFRPDE5AMAPT
SCHEMBL8796323 0.86 EGFR (0.48) PDGFRBMAPK1L3MBTL1EGFRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-12-19 US disclosed
US-6127541-A 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-10-03 US disclosed
EP-0863144-A1 IMIDAZOQUINAZOLINE DERIVATIVES Kyowa Hakko Co., Ltd. (JP) 1998-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives MKI67, HRAS, VHL PDGFRB 3113/4885MAPK1 1224/4885L3MBTL1 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.